Furthermore, the appetite score was significantly higher at 5 hours, suggesting a decreased appetite, and the amount of food consumed was about 16% lower [7]
Patient uptake estimates that between 25 and 30 million Americans could be using GLP-1 therapies by 2030, up from approximately 10 million in 2026
These medications typically require indefinite use for weight management effectiveness
Potential risks involve immune modulation and unknown long-term effects due to limited human data
Exploring the Role of Circadian Rhythms in Sleep and Recovery: A Review Article
Interventional studies have shown that pharmacological agents targeting metabolic and hemodynamic stress, such as SGLT2 inhibitors, GLP-1 receptor agonists, and renin-angiotensin system blockers, can partially restore plasma and urinary acylcarnitine levels